Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection

Clinical and Vaccine Immunology

Volumn 19, Issue 7, 2012, Pages 979-990

  Okamoto, Shigefumi ^a   Matsuoka, Sumiko ^a   Takenaka, Nobuyuki ^a   Haredy, Ahmad M ^a   Tanimoto, Takeshi ^b   Gomi, Yasuyuki ^b   Ishikawa, Toyokazu ^b   Akagi, Takami ^c   Akashi, Mitsuru ^c   Okuno, Yoshinobu ^b   Mori, Yasuko ^a,d   Yamanishi, Koichi ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b Osaka University   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CROSS PROTECTION; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRAL CLEARANCE; VIRION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; CROSS PROTECTION; FEMALE; INFLUENZA A VIRUS; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; NASAL MUCOSA; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, INACTIVATED;

EID: 84863552260     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00016-12     Document Type: Article

References (32)

1. Agrawal AS, et al. 2010. Genetic characterization of circulating seasonal influenza A viruses (2005-2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India. Infect. Genet. Evol. 10:1188-1198.
2. Akagi T, Kaneko T, Kida T, Akashi M. 2005. Preparation and characterization of biodegradable nanoparticles based on poly(gamma-glutamic acid) with L-Phenylalanine as a protein carrier. J. Control Rel. 108:226-236. (Pubitemid 41608656)
3. Amorij JP, Hinrichs W, Frijlink HW, Wilschut JC, Huckriede A. 2010. Needle-free influenza vaccination. Lancet Infect. Dis. 10:699-711.
4. Bean WJ, et al. 1992. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J. Virol. 66:1129-1138.
5. Belshe RB. 2004. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 103:177-185. (Pubitemid 38649077)
6. Bennink JR, Yewdell JW, Smith GL, Moss B. 1986. Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J. Virol. 57:786-791. (Pubitemid 16143957)
7. Furuya Y, et al. 2010. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by gamma-irradiated influenza A viruses. J. Virol. 84:4212-4221.
8. Ichinohe T, et al. 2005. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79:2910-2919. (Pubitemid 40270569)
9. Ito R, et al. 2003. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 21:2362-2371. (Pubitemid 36561328)
10. Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC. 2004. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304:1808-1810. (Pubitemid 38787898)
11. Kikuta K, et al. 1990. Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit. Vaccine 8:595-599.
12. Koyama S, et al. 2010. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci. Transl. Med. 2:25ra24. doi: 10.1126/scitranslmed.3000759.
13. Mizuno D, Ide-Kurihara M, Ichinomiya T, Kubo I, Kido H. 2006. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J. Immunol. 176:1122-1130. (Pubitemid 43099714)
14. Okamoto S, et al. 2009. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine 27:5896-5905.
15. Okamoto S, et al. 2007. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Vaccine 25:8270-8278. (Pubitemid 350087384)
16. Okamoto S, et al. 2008. Single dose of inactivated Japanese encephalitis vaccine with poly(gamma-glutamic acid) nanoparticles provides effective protection from Japanese encephalitis virus. Vaccine 26:589-594.
17. Price GE, Gaszewska-Mastarlarz A, Moskophidis D. 2000. The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. J. Virol. 74:3996-4003. (Pubitemid 30214404)
18. Quan FS, Compans RW, Nguyen HH, Kang SM. 2008. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82:1350-1359.
19. Rowe T, et al. 1999. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37:937-943. (Pubitemid 29140593)
20. Smirnov YA, Gitelman AK, Govorkova EA, Lipatov AS, Kaverin NV. 2004. Influenza H5 virus escape mutants: immune protection and antibody production in mice. Virus Res. 99:205-208. (Pubitemid 38124495)
21. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. 2003. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21:3212-3218. (Pubitemid 36700428)
22. Takenaka N, et al. 2011. Overexpression of phospholipase Cepsilon in keratinocytes upregulates cytokine expression and causes dermatitis with acanthosis and T-cell infiltration. Eur. J. Immunol. 41:202-213.
23. Tamura S. 2010. Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine 28:6393-6397.
24. Tamura S, et al. 1991. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur. J. Immunol. 21:1337-1344.
25. Tamura S, Hasegawa H, Kurata T. 2010. Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn. J. Infect. Dis. 63:8-15.
26. Tamura S, et al. 1992. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol. 149:981-988.
27. Tamura SI, et al. 1992. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur. J. Immunol. 22:477-481.
28. Tumpey TM, Renshaw M, Clements JD, Katz JM. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150. (Pubitemid 32448536)
29. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. 1992. Evolution and ecology of influenza A viruses. Microbiol. Rev. 56:152-179.
30. Wolf AI, et al. 2009. Plasmacytoid dendritic cells are dispensable during primary influenza virus infection. J. Immunol. 182:871-879.
31. Wright PF, Neuman G, Kawaoka Y. 2007. Orthomyxoviruses, p 1691-1740. In Knipe DM et al (ed), Fields virology, 5th ed. Lippincott-Raven, Philadelphia, PA.
32. Yewdell JW, Bennink JR, Smith GL, Moss B. 1985. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 82:1785-1789. (Pubitemid 15085262)